INCHEON, Korea, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced results from two real-world studies of RENFLEXIS ® (infliximab-abda) in patients with Inflammatory Bowel ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the U.S. launch of RENFLEXIS™ (infliximab-abda), a biosimilar of the originator ...

A recent study evaluated the efficacy, safety, and immunogenicity of switching from reference infliximab (Remicade®, Janssen Biotech), to the biosimilar SB2 (Renflexis®, Samsung Bioepis), in patients ...

Merck & Co. today said it has launched in the U.S. a biosimilar of Remicade ® (infliximab), the blockbuster immune-mediated inflammatory disorders treatment it markets outside the U.S., including ...

Samsung Bioepis Co., Ltd. today announced the launch of RENFLEXIS ™ (infliximab-abda), a biosimilar referencing Remicade ® (infliximab), in the United States (US). RENFLEXIS ™ was developed by Samsung ...

Infliximab products work by neutralizing the biological activity of TNF-alpha by binding with high affinity to the soluble and transmembrane forms of TNF-alpha and inhibiting the binding of TNF-alpha ...

The US Food and Drug Administration (FDA) has approved the infliximab biosimilar product infliximab-abda (Renflexis, Samsung Bioepis) for multiple indications. A biosimilar product is based on a ...

Johnson & Johnson’s inflammatory diseases blockbuster Remicade (infliximab) faces further US competition after the FDA granted a licence for Samsung Bioepis’ biosimilar, Renflexis, in all the ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Researchers have observed a “modest uptake” in the use of biosimilars for infliximab in the past 18 ...

INCHEON, Korea – December 4, 2015 – Samsung Bioepis Co., Ltd. today announced that Korea's Ministry of Food and Drug Safety (MFDS) has approved RENFLEXIS® – a biosimilar version of Remicade® ...

A biosimilar product must demonstrate no clinically meaningful differences in safety or efficacy from the reference product. Like Remicade, Renflexis is a tumor necrosis factor (TNF) blocker indicated ...